Sugi Predict

Sugi Predict / Compounds / SCHEMBL2654873

SCHEMBL2654873

SCHEMBL2654873

CCOC(=O)CCNC(=O)c1ccc(C(NC(=O)Nc2cc(Cl)cc(Cl)c2)c2ccc(C3=CCCCC3)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 12/20 0.53
▸ GIPR P48546 9/20 0.53
▸ GLP1R P43220 4/20 0.53
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ MCHR1 Q99705 2/20 0.37
▸ KMT2A Q03164 2/20 0.35
▸ GAA P10253 1/20 0.35
▸ MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2652200 0.88 GCGR (0.67) GCGRGIPRGLP1RNPC1RAB9A
SCHEMBL2646852 0.87 GCGR (0.56) GCGRGIPRGLP1RALDH1A1MCHR1
SCHEMBL2647929 0.87 GCGR (0.56) GCGRGIPRGLP1RALDH1A1MCHR1
SCHEMBL2656024 0.83 GCGR (0.54) GCGRGIPRGLP1RMCHR1
SCHEMBL2654867 0.82 GCGR (0.79) GCGRGIPRGLP1RKMT2A
SCHEMBL6293014 0.82 GCGR (0.70) GCGRGIPRGLP1RMCHR1
SCHEMBL2650113 0.81 GCGR (0.57) GCGRGIPRGLP1RNPC1RAB9A
SCHEMBL2643365 0.81 GCGR (0.49) GCGRGIPRGLP1RALDH1A1MCHR1
SCHEMBL2654184 0.81 GCGR (0.69) GCGRGIPRGLP1RMCHR1
SCHEMBL2651577 0.81 GCGR (0.69) GCGRGIPRGLP1RMCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed
EP-1183229-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-03-06 — — EP disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GIPR 4/4885GLP1R 1/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885GIPR 4/4885GLP1R 1/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GIPR 4/4885GLP1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.